Investigating the role of BMAL1 in tissue damage after spinal cord injury
BMAL1/ARNTL plays a critical, non-circadian role in secondary tissue damage after contusive SCI
This study is looking at how a specific gene called BMAL1 might help protect brain cells after a spinal cord injury, with the hope of finding new ways to improve recovery for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project ID | NIH-10874439 on NIH RePORTER |
What this research studies
This research explores how the BMAL1/ARNTL gene influences tissue damage following spinal cord injuries (SCI). It focuses on understanding the non-circadian functions of BMAL1, particularly its role in protecting brain cells from oxidative stress and apoptosis. By examining the gene's activity in response to SCI, the research aims to uncover new therapeutic targets that could improve recovery outcomes. Patients may benefit from insights that could lead to innovative treatments for spinal cord injuries.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced a spinal cord injury and are seeking potential new treatment options.
Not a fit: Patients with chronic spinal cord injuries or those who do not have active tissue damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance recovery and reduce secondary damage after spinal cord injuries.
How similar studies have performed: While the role of circadian rhythms in health is well-studied, the specific investigation of BMAL1's non-circadian functions in spinal cord injury is a novel approach.
Where this research is happening
Louisville, United States
- University of Louisville — Louisville, United States (Active)
Researchers
- Principal investigator: Hetman, Michal — University of Louisville
- Study coordinator: Hetman, Michal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.